Lisa L Abuogi1, Jose Castillo-Mancilla2, Karen Hampanda3, Kevin Owuor4, Tobias Odwar5, Maricianah Onono5, Anna Helova6, Janet M Turan6, Peter L Anderson4. 1. Department of Pediatrics, University of Colorado Denver, Aurora, CO. 2. Division of Infectious Diseases, Department of Medicine, University of Colorado Denver, Aurora, CO. 3. School of Public Health, University of Colorado Denver, Aurora, CO. 4. Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO. 5. Centre for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya; and. 6. Department of Health Care Organization and Policy, School of Public Health, University of Alabama at Birmingham, Birmingham, AL.
Abstract
BACKGROUND: Adherence to antiretroviral therapy (ART) among pregnant and postpartum women with HIV (PWLWH) is critical to promote maternal health and prevent HIV transmission. Tenofovir diphosphate (TFV-DP) in dried blood spots (DBS) is an objective assessment of cumulative ART adherence that has not been fully assessed in PWLWH. SETTING: Southwestern Kenya. METHODS: PWLWH receiving tenofovir disoproxil fumarate-based ART from 24 health facilities provided DBS samples at 3 time points [pregnancy/early postpartum (PP), 6 months PP, and 9-12 months PP]. Thresholds for daily adherence were defined as TFV-DP in DBS ≥650 fmol/punch in pregnancy and ≥950 PP. Descriptive analysis is presented. Cluster adjusted χ2 and t-tests were used to test for association with clinical and demographic factors. RESULTS: A total of 419 DBS samples were collected from 150 PWLWH. Median TFV-DP in DBS was lowest, 552 fmol/punch [interquartile range (IQR), 395-759] in pregnancy and declined over time [914 (IQR, 644-1176) fmol/punch; early PP; 838 (IQR, 613-1063) fmol/punch 6 months PP; and 785 (IQR, 510-1009) fmol/punch 9-12 months; P < 0.001]. Only 42% of samples in pregnancy and 38.5% of samples in PP met thresholds for daily adherence. Clinical or demographic factors were not associated with suboptimal adherence levels. CONCLUSION: Cumulative ART exposure in PWLWH, quantified by TFV-DP in DBS, demonstrated a stepwise decrease (ie, adherence) PP. Most women demonstrated less than daily adherence throughout the peripartum period. Use of TFV-DP in DBS as a measure of cumulative ART adherence could help optimize health outcomes in PWLWH and their infants.
BACKGROUND: Adherence to antiretroviral therapy (ART) among pregnant and postpartum women with HIV (PWLWH) is critical to promote maternal health and prevent HIV transmission. Tenofovir diphosphate (TFV-DP) in dried blood spots (DBS) is an objective assessment of cumulative ART adherence that has not been fully assessed in PWLWH. SETTING: Southwestern Kenya. METHODS: PWLWH receiving tenofovir disoproxil fumarate-based ART from 24 health facilities provided DBS samples at 3 time points [pregnancy/early postpartum (PP), 6 months PP, and 9-12 months PP]. Thresholds for daily adherence were defined as TFV-DP in DBS ≥650 fmol/punch in pregnancy and ≥950 PP. Descriptive analysis is presented. Cluster adjusted χ2 and t-tests were used to test for association with clinical and demographic factors. RESULTS: A total of 419 DBS samples were collected from 150 PWLWH. Median TFV-DP in DBS was lowest, 552 fmol/punch [interquartile range (IQR), 395-759] in pregnancy and declined over time [914 (IQR, 644-1176) fmol/punch; early PP; 838 (IQR, 613-1063) fmol/punch 6 months PP; and 785 (IQR, 510-1009) fmol/punch 9-12 months; P < 0.001]. Only 42% of samples in pregnancy and 38.5% of samples in PP met thresholds for daily adherence. Clinical or demographic factors were not associated with suboptimal adherence levels. CONCLUSION: Cumulative ART exposure in PWLWH, quantified by TFV-DP in DBS, demonstrated a stepwise decrease (ie, adherence) PP. Most women demonstrated less than daily adherence throughout the peripartum period. Use of TFV-DP in DBS as a measure of cumulative ART adherence could help optimize health outcomes in PWLWH and their infants.
Authors: Maricianah Onono; Tobias Odwar; Lisa Abuogi; Kevin Owuor; Anna Helova; Elizabeth Bukusi; Janet Turan; Karen Hampanda Journal: AIDS Behav Date: 2020-06
Authors: Lauren Jennings; Reuben N Robbins; Nadia Nguyen; Christopher Ferraris; Cheng-Shiun Leu; Curtis Dolezal; Nei-Yuan Hsiao; Ofole Mgbako; John Joska; Jose R Castillo-Mancilla; Landon Myer; Peter L Anderson; Robert H Remien; Catherine Orrell Journal: AIDS Date: 2022-02-16 Impact factor: 4.632
Authors: Albert Y Liu; Stephanie E Cohen; Eric Vittinghoff; Peter L Anderson; Susanne Doblecki-Lewis; Oliver Bacon; Wairimu Chege; Brian S Postle; Tim Matheson; K Rivet Amico; Teri Liegler; M Keith Rawlings; Nikole Trainor; Robert Wilder Blue; Yannine Estrada; Megan E Coleman; Gabriel Cardenas; Daniel J Feaster; Robert Grant; Susan S Philip; Richard Elion; Susan Buchbinder; Michael A Kolber Journal: JAMA Intern Med Date: 2016-01 Impact factor: 21.873
Authors: Deborah J Donnell; Jared M Baeten; Ting Hong; Jairam R Lingappa; Andrew Mujugira; Edith Nakku-Joloba; David Bangsberg; Connie Celum Journal: AIDS Behav Date: 2013-02
Authors: Lynda Stranix-Chibanda; Peter L Anderson; Deborah Kacanek; Sybil Hosek; Sharon Huang; Teacler G Nematadzira; Frank Taulo; Violet Korutaro; Clemensia Nakabiito; Maysebole Masenya; Kathryn Lypen; Emily Brown; Mustafa E Ibrahim; Jenna Yager; Lubbe Wiesner; Benjamin Johnston; K Rivet Amico; James F Rooney; Nahida Chakhtoura; Hans M L Spiegel; Benjamin H Chi Journal: Clin Infect Dis Date: 2021-10-05 Impact factor: 20.999
Authors: Jenna Lynn Yager; Ryan Patrick Coyle; Stacey Summer Coleman; Lucas Ellison; Jia-Hua Zheng; Lane Bushman; Edward Michael Gardner; Mary Morrow; Samantha MaWhinney; Peter L Anderson; Jennifer Justice Kiser; Jose Ramon Castillo-Mancilla Journal: J Int Assoc Provid AIDS Care Date: 2019 Jan-Dec